GeneFluidics is the only group selected for both NIAID antimicrobial resistance diagnostics projects (https://www.nih.gov/news-events/news-releases/nih-funds-nine-antimicrobial-resistance-diagnostics-projects) and as finalists for the NIH AMR Challenge Step 2 (https://dpcpsi.nih.gov/AMRChallenge/Finalists). - December 05, 2018
GeneFluidics, a molecular diagnostics company specializing in the development of diagnostics solutions for infectious diseases, today announced CE marking for UtiMax™ under the Directive 98/79/EC on in vitro diagnostic medical devices. UtiMax™has successfully completed a multicenter validation study and clinical testing. It does not require clinical isolates from urine cultures, enabling a rapid ID reporting in as short as 30 minutes and AST in 120 minutes for a positive ID result. - December 10, 2017
GeneFluidics, Inc. is pleased to announce that their Proteus Robotic System has received the New Product Award from the Association for Laboratory Automation (ALA) at LabAutomation2009.
The ALA is an international organization devoted to the study, development, and use of laboratory automation. Their... - February 03, 2009